Novo Nordisk - Company Information
Novo Nordisk A/S is a global healthcare company engaged in the discovery, development, manufacturing, and marketing of pharmaceutical products, focusi...Read more
Headquarters
Contact
Linkedin
Company Size10,000+
Stock SymbolNVO
Websitenovonordisk.com
TypePublic
Novo Nordisk Technology Stack
Find prospects by the technologies they use. Use this section to learn more about key technologies and tools, tracked by 6sense, used by Novo Nordisk
Novo Nordisk Employee Profiles
Are you looking for the decision-makers at Novo Nordisk? Get their email address, phone numbers, and other details from Linkedin or any website. Install and uncover Novo Nordisk’s employee details in less than 30 secs.
Sign-up for 6sense Revenue AI™ for Sales
To find emails, direct dials, and more for prospects across the web.
Sign Up TodayDownload the 6sense Chrome Extension to get verified contact data of Novo Nordisk employees
Install Now
Novo Nordisk News & Press Releases
Sales prospecting needs to be timely and appropriate for the person and organization you are contacting. Following the most recent company news, alerts, and updates about the leads you are currently working on is the simplest and most convenient way to stay on top of them. Here are Novo Nordisk latest news, alerts and updates.
Wegovy maker Novo Nordisk signs research partnerships with U.S. biotech firms
Blockbuster weight-loss drug maker Novo Nordisk announced on Thursday research collaborations with two U.S. biotech firms, part of its efforts to stay ahead in big pharma's race to develop more treatments for cardiometabolic diseases.
4 Jan 2024
Diving into CVD? Novo Nordisk to acquire KBP’s hypertension drug for $1.3B
Danish obesity and diabetes drugmaker Novo Nordisk A/S is set to acquire the Singapore-based KBP Biosciences Co. Ltd.™s hypertension drug, ocedurenone (KBP-5074), for potentially $1.3 billion, creating a platform to increase its reach in the cardiovascular (CV) landscape beyond a crowding obesity market.
17 Oct 2023
Novo Nordisk to acquire ocedurenone for uncontrolled hypertension from KBP Biosciences
Novo Nordisk A/S and KBP Biosciences PTE., Ltd. today announced that Novo Nordisk has agreed to acquire ocedurenone for uncontrolled hypertension with potential application in cardiovascular and kidney disease from KBP Biosciences for up to 1.
16 Oct 2023
Novo Nordisk to acquire obesity drug developer Inversago
Inversago is a privately owned company which develops therapies pitched at people with obesity, diabetes and metabolic disorders, the Novo Nordisk said in its second-quarter report. Inversago's lead asset is INV-202,
11 Aug 2023
Novo Nordisk plans to acquire Canadian obesity drug maker Inversago
Drug manufacturer Novo Nordisk announced Thursday that it will acquire Inversago Pharma, a Montreal-based company that develops potential treatments for obesity, if certain research conditions are met,
10 Aug 2023
Completion of Novo Nordisk's Acquisition of a Controlling Stake in BIOCORP
ISSOIRE, France, August 04, 2023--(BUSINESS WIRE)--Regulatory News: Following the announcement of the planned acquisition of BIOCORP Production SA (FR0012788065 - ALCOR) ("BIOCORP") by NOVO NORDISK (DK0060534915 - Novo-B), a leading global healthcare ...
6 Aug 2023
FAQs for Novo Nordisk
Explore frequently asked questions about Novo Nordisk’s business, including founding details, header quarters, information on technology stack, industry listing, and other details.
What is Novo Nordisk's official website?
The official website of Novo Nordisk is novonordisk.com You can find their contact number, email address, and headquarters by clicking here.
How many employees are working at Novo Nordisk?
What industry is Novo Nordisk in?
What is Novo Nordisk's tech stack?
Where are Novo Nordisk's headquarters?
Get instant access to B2B contact data across the web
Sign Up Today
